On Tuesday, May 28, Qualcomm asked a federal judge not to enforce her decision that it illegally squeezed out rivals in the smartphone chips market as it plans to file an appeal that could take more than a year to wind through the courts, reported Reuters.
In a filing in federal court in San Jose, California, Qualcomm stated that it believes it can succeed in appealing the May 21 decision by US District Judge Lucy Koh in an antitrust case brought by the US Federal Trade Commission (FTC) in January 2017. The company has not yet filed that appeal; Tuesday’s filing only concerns whether the ruling’s provisions will be put on hold temporarily as it plays out.
Qualcomm argued that Koh’s ruling raised “serious legal questions” because, among other things, she excluded evidence after a March 2018 cutoff date—including the fact that Apple dropped Qualcomm in favor of rival chip supplier Intel—showing that Qualcomm did not have a stranglehold on the market. Qualcomm also claimed that the FTC’s theory in the lawsuit – that Qualcomm’s patent licensing practices amounted to a “tax” on smartphone makers—generating profits that Qualcomm then put to work undercutting its rivals—was unprecedented in antitrust law.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Judge Signals Revisions Likely in DOJ Case Targeting Live Nation Monopoly
Jan 22, 2025 by
CPI
American Airlines and JetBlue Agree to $2 Million Legal Fee Settlement with U.S. States
Jan 22, 2025 by
CPI
Federal Judge Dismisses Class Action Alleging Inflated Yacht Commission Fees
Jan 22, 2025 by
CPI
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan